Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.
DBV Technologies, developing a family of skin patch immunotherapies for common food allergies, announced positive results of their Phase II clinical trial of Viaskin Milk.
Enrolled in the trial were 198 children ages 2 to 17 randomized to receive one of three doses of Viaskin Milk or placebo every day for a year. Of the 38 children ages 2 to 11 years who received the 300µg (middle) dose of Viaskin Milk, 58% responded to the therapy, compared to 32% of children of the same age in receiving placebo.
Allergy Therapeutics, a UK-based pharmaceutical company specializing in the development of allergy vaccines, announced they have signed a contract with AGC Biologics to scale up the manufacturing of their Polyvac® Peanut product for use in clinical studies. As we reported this time last year, the company announced positive results from its preclinical trial.
Polyvac Peanut contains virus-like particles combined with recombinant peanut allergen. The company claims the therapy induces protective immunity, protects against anaphylaxis when challenged with peanut, and has a safety profile similar to that of placebo.
- Allergy Therapeutics plc Prepares for Manufacturing and Clinical Development of Polyvac – Company Press Release
- DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients – Company Press Release